MedPath

Clevidipine

Generic Name
Clevidipine
Brand Names
Cleviprex
Drug Type
Small Molecule
Chemical Formula
C21H23Cl2NO6
CAS Number
167221-71-8
Unique Ingredient Identifier
19O2GP3B7Q
Background

Clevidipine is a dihydropyridine L-type calcium channel blocker that is selective for vascular smooth muscle and is indicated for blood pressure reduction when oral therapy is not an option.

Indication

For the reduction of blood pressure when when oral antihypertensive therapy is not feasible or not desirable.

Associated Conditions
Hypertension
Clinical Trials
Related News

Clevidipine for the Antihypertensive Treatment of Acute Intracerebral Hemorrhage

Not yet recruiting
Conditions
Hypertension
Intracerebral Hemorrhage
Stroke
Interventions
Drug: Alternate IV Antihypertensive Regimen
First Posted Date
2024-05-07
Last Posted Date
2024-05-07
Lead Sponsor
Zeenat Qureshi Stroke Institute
Target Recruit Count
1000
Registration Number
NCT06402968

Effect of Treatment of Pre-induction Hypertension on Hemodynamic Stability During Induction of General Anesthesia

Phase 4
Not yet recruiting
Conditions
Hypertension
Interventions
Drug: Lactated Ringers, Intravenous
First Posted Date
2023-10-03
Last Posted Date
2024-11-08
Lead Sponsor
University of California, San Diego
Target Recruit Count
64
Registration Number
NCT06063772

a Study Evaluating the Safety and Efficacy of Clevidipine for Patients Who With Hypertensive Emergency and Sub-emergency

Phase 3
Not yet recruiting
Conditions
Hypertensive Emergency
Interventions
First Posted Date
2023-06-28
Last Posted Date
2023-06-28
Lead Sponsor
Qilu Pharmaceutical (Hainan) Co., Ltd.
Target Recruit Count
378
Registration Number
NCT05922436

A Study of Clevidipine Butyrate Injectable Emulsion in the Treatment of Hypertensive Emergency and Sub-emergency

Phase 3
Not yet recruiting
Conditions
Hypertensive Emergency
Interventions
First Posted Date
2023-03-24
Last Posted Date
2023-03-24
Lead Sponsor
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Target Recruit Count
398
Registration Number
NCT05783557

Clevidipine Infusion for Blood Pressure Management After Successful Revascularization in Acute Ischemic Stroke

Phase 3
Completed
Conditions
Stroke, Acute
Blood Pressure
Mechanical Thrombectomy
Interventions
First Posted Date
2022-01-03
Last Posted Date
2025-01-07
Lead Sponsor
ProMedica Health System
Target Recruit Count
80
Registration Number
NCT05175547
Locations
🇺🇸

ProMedica Toledo Hospital, Toledo, Ohio, United States

Clevidipine in Neurocritical Patients

Completed
Conditions
High Blood Pressure
First Posted Date
2021-12-23
Last Posted Date
2021-12-23
Lead Sponsor
Hospital de Cruces
Target Recruit Count
33
Registration Number
NCT05168059
Locations
🇪🇸

Biocruces, Barakaldo, Vizcaya, Spain

Safety and Efficacy Study of Clevidipine Butyrate Injection in Hypertensive Emergencies

Phase 3
Conditions
Hypertensive Emergency
Interventions
Drug: Ncardipine Hydrochloride Injection
First Posted Date
2020-12-17
Last Posted Date
2020-12-17
Lead Sponsor
Nanjing Yoko Biomedical Co., Ltd.
Target Recruit Count
262
Registration Number
NCT04670809
Locations
🇨🇳

Beijing Anzhen Hospital，Capital Medical University, Beijing, China

🇨🇳

Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China

Effect of Changing Physiological Conditions on Myogenic Oscillations: Pilot Study

Early Phase 1
Completed
Conditions
Vascular Diseases
Interventions
Other: Increased venous pressure
Other: tetanic stimulus
First Posted Date
2018-10-25
Last Posted Date
2022-06-30
Lead Sponsor
University of California, San Francisco
Target Recruit Count
40
Registration Number
NCT03719001
Locations
🇺🇸

University of California San Francisco, San Francisco, California, United States

Clevidipine (Cleviprex®) Compared With Urapidil (Ebrantil®)

Phase 4
Withdrawn
Conditions
Nontraumatic Intracerebral Hemorrhage, Multiple Localized
Interventions
First Posted Date
2017-10-03
Last Posted Date
2021-11-08
Lead Sponsor
University of Zurich
Registration Number
NCT03300479
Locations
🇨🇭

University Hospital Zurich, Zurich, Switzerland

Clevidipine for Vasospasm After Subarachnoid Hemorrhage (SAH)

Phase 2
Withdrawn
Conditions
Subarachnoid Hemorrhage
Cerebral Aneurysm
Vasospasm, Intracranial
Interventions
First Posted Date
2013-12-13
Last Posted Date
2023-02-01
Lead Sponsor
Henry Ford Health System
Registration Number
NCT02011321
Locations
🇺🇸

Henry Ford hospital, Detroit, Michigan, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy